Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants. It is developing bioengineered organ implants, which addresses the damage of the esophagus, bronchus, and trachea due to cancer, infection, trauma, or congenital abnormalities. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone774-233-7300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$80,000.00
Profitability
Miscellaneous
Employees15
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Biostage (OTCMKTS:BSTG) Frequently Asked Questions
What is Biostage's stock symbol?
Biostage trades on the OTCMKTS under the ticker symbol "BSTG."
How were Biostage's earnings last quarter?
Biostage Inc (OTCMKTS:BSTG) released its earnings results on Tuesday, August, 13th. The company reported ($0.37) earnings per share for the quarter. View Biostage's Earnings History.
When is Biostage's next earnings date?
Has Biostage been receiving favorable news coverage?
Media coverage about BSTG stock has trended somewhat positive this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Biostage earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Biostage.
Who are some of Biostage's key competitors?
Some companies that are related to Biostage include Nephros (NEPH), Apollo Endosurgery (APEN), Endologix (ELGX), STRATA Skin Sciences (SSKN), Pro-Dex (PDEX), AIT Therapeutics (AITB), BeyondAirInc . (XAIR), Nephros (NEPHD), Motus GI (MOTS), Invo Bioscience (IVOB), SANUWAVE Health (SNWV), Interpace Diagnostics Group (IDXG), PAVmed (PAVM), Arch Therapeutics (ARTH) and Neovasc (NVCN).
What other stocks do shareholders of Biostage own?
Who are Biostage's key executives?
Biostage's management team includes the folowing people:
- Mr. James J. McGorry, CEO & Director (Age 63)
- Mr. Thomas W. McNaughton, CFO & Sec. (Age 59)
- Yu Hong, Pres (Age 46)
- Ms. Ginger A. Abraham-Freel, Director of Quality & Operations
- Dr. William L. Fodor Ph.D., Chief Scientific Officer (Age 60)
How do I buy shares of Biostage?
Shares of BSTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Biostage's stock price today?
One share of BSTG stock can currently be purchased for approximately $2.29.
How big of a company is Biostage?
What is Biostage's official website?
How can I contact Biostage?
Biostage's mailing address is 84 October Hill Road Suite 11, Holliston MA, 01746. The company can be reached via phone at 774-233-7300 or via email at [email protected]
MarketBeat Community Rating for Biostage (OTCMKTS BSTG)
| Community Ranking: | | 3.1 out of 5 ( ) |
| Outperform Votes: | | 36 (Thanks for Voting!) |
| Underperform Votes: | | 23 (Thanks for Voting!) |
| Total Votes: | | 59 |
